Liles Scott
Known title: President, Medical and VetCIK: 0002016253
Associated companies
Transaction History
| CVSA | ▼ Sell | Tax Withholding | 448 | $50K | 4/15/2026 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 407 | $39K | 11/13/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 2,613 | $253K | 11/12/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 6,844 | $923K | 8/23/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 2,784 | $376K | 8/23/2025 | View on chart |
| CVSA | ▼ Sell | Tax Withholding | 458 | $49K | 4/15/2025 | View on chart |
| CVSA | ▲ Buy | Grant | 2,990 | $269K | 11/13/2024 | View on chart |
| CVSA | ▲ Buy | Grant | 3,290 | $150K | 4/15/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Covista receives mixed analyst coverage and rating update
Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.
Covista receives mixed analyst coverage and rating update. Recent commentary on Covista is mixed. ChartMill describes the stock as a GARP case with reasonable growth and valuation. Yahoo published both a target‑focused piece and a separate article highlighting reasons to avoid the stock. BMO Capital kept an Outperform rating but lowered its price target to $145.